Mira Pharmaceuticals Inc (MIRA)

10:23 AM

Pharmaceutical Stock Jumps After Key Trial Findings - MSN

10:23 AM

04:23 AM

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) Short Interest Down 14.1% in April - Defense World

04:23 AM

Apr 27, 2025

Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com

Apr 27, 2025

Apr 24, 2025

Mira Pharmaceuticals Inc [MIRA] moved up 7.08: Why It’s Important - dbtnews.com

Apr 24, 2025

Apr 24, 2025

Financial Metrics Unveiled: Mira Pharmaceuticals Inc (MIRA)’s Key Ratios in the Spotlight - DWinneX

Apr 24, 2025

Apr 23, 2025

MIRA Pharmaceuticals reports positive in vitro drug release data for topical Ketamir-2 - MSN

Apr 23, 2025

Apr 23, 2025

Mira Pharmaceuticals announces key drug development milestone By Investing.com - Investing.com Canada

Apr 23, 2025

Apr 23, 2025

Mira Pharmaceuticals announces key drug development milestone - Investing.com Australia

Apr 23, 2025

Apr 23, 2025

MIRA Pharmaceuticals (MIRA) Advances Ketamir-2 Formulations in P - GuruFocus

Apr 23, 2025

Apr 23, 2025

MIRA Pharmaceuticals reports positive Ketamir-2 study By Investing.com - Investing.com India

Apr 23, 2025

Apr 23, 2025

MIRA Pharmaceuticals reports positive Ketamir-2 study - Investing.com

Apr 23, 2025

Apr 23, 2025

MIRA Pharmaceuticals Reports Positive In Vitro Drug Release Data for Topical Ketamir-2, Targeting $11B+ U.S. Topical Pain Relief Market and Exploring FDA Fast Track Designation - Weatherford Democrat

Apr 23, 2025

Apr 23, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 23, 2025

Apr 23, 2025

MIRA's Novel Pain Treatment Delivers Positive Data, Targets Massive $11.5B Market With Fast-Track Potential - Stock Titan

Apr 23, 2025

Apr 22, 2025

Mira Pharmaceuticals Inc (MIRA) is a good investment, but the stock may be undervalued - uspostnews.com

Apr 22, 2025

Apr 21, 2025

MIRA’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - investchronicle.com

Apr 21, 2025

Apr 18, 2025

Promising Canadian Stocks To Follow Now – April 16th - Defense World

Apr 18, 2025

Apr 17, 2025

Is Mira Pharmaceuticals Gaining or Losing Market Support? - Benzinga

Apr 17, 2025

Apr 16, 2025

US Health Care Stocks Face Mixed Results With Sector's Broad Decline - Finimize

Apr 16, 2025

Apr 16, 2025

MIRA reports Ketamir-2 shows promise in diabetic neuropathy study By Investing.com - Investing.com South Africa

Apr 16, 2025

Apr 16, 2025

Mira Says Diabetes Treatment Ketamir-2 Shows Significant Reduction in Neuropathic Pain Symptoms in Animal Model - marketscreener.com

Apr 16, 2025

Apr 16, 2025

MIRA reports Ketamir-2 shows promise in diabetic neuropathy study - Investing.com Australia

Apr 16, 2025

Apr 16, 2025

MIRA Pharmaceuticals reports positive Ketamir-2 study results - Investing.com

Apr 16, 2025

Apr 16, 2025

MIRA Pharmaceuticals reports positive Ketamir-2 study results By Investing.com - Investing.com Canada

Apr 16, 2025

Apr 16, 2025

MIRA Pharmaceuticals Announces Positive Results for Ketamir-2 in Diabetic Neuropathy Animal Model, Reinforcing Confidence Ahead of Phase I Completion - standard-journal.com

Apr 16, 2025

Apr 16, 2025

Game-Changing Results: New Oral Ketamine Drug Outperforms FDA-Approved Pain Medications - Stock Titan

Apr 16, 2025

Apr 16, 2025

Mira Pharmaceuticals IncAnnounces Positive Study Results For Ketamir-2 - marketscreener.com

Apr 16, 2025

Apr 16, 2025

EXCLUSIVE: MIRA Pharmaceuticals Ketamir-2 Shows Efficacy In Diabetes-Associated Nerve Damage In Animal Study - Benzinga

Apr 16, 2025

Apr 16, 2025

Mira Pharmaceuticals Inc’s Mixed Bag: Down -0.91% in 6 Months, Down -9.38% in 30 Days - investchronicle.com

Apr 16, 2025

Apr 12, 2025

Mira Pharmaceuticals faces Nasdaq delisting over equity - Investing.com Australia

Apr 12, 2025

Apr 11, 2025

Mira Pharmaceuticals faces Nasdaq delisting over equity By Investing.com - Investing.com South Africa

Apr 11, 2025

Apr 04, 2025

MIRA Mira Pharmaceuticals files $100M mixed securities shelf - MSN

Apr 04, 2025

Apr 04, 2025

Equities Analysts Issue Forecasts for MIRA FY2026 Earnings - Defense World

Apr 04, 2025

Apr 01, 2025

MIRA Pharmaceuticals begins Phase 1 trial for pain treatment - Investing.com Australia

Apr 01, 2025

Apr 01, 2025

MIRA Pharmaceuticals begins Phase 1 trial for pain treatment By Investing.com - Investing.com Philippines

Apr 01, 2025

Apr 01, 2025

MIRA Pharmaceuticals Enrolls First Subjects in Phase 1 Clinical Trial of Ketamir-2 for Neuropathic Pain - guardonline.com

Apr 01, 2025

Apr 01, 2025

Game-Changing Pain Treatment Enters Clinical Trials: Superior to Current Options in Early Data - Stock Titan

Apr 01, 2025

Apr 01, 2025

63,410 Shares in MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) Purchased by Virtu Financial LLC - Defense World

Apr 01, 2025

Mar 31, 2025

MIRA Pharmaceuticals (MIRA) Expected to Announce Earnings on Monday - Defense World

Mar 31, 2025

Mar 31, 2025

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) Short Interest Up 38.9% in March - Defense World

Mar 31, 2025

Mar 28, 2025

MIRA Pharmaceuticals Inc. (MIRA) reports earnings - Quartz

Mar 28, 2025

Mar 28, 2025

MIRA Pharmaceuticals (NASDAQ:MIRA) Stock Price Down 4.3% – Here’s What Happened - Defense World

Mar 28, 2025